LCN2 and renal fibrosis: Confirming our dose range experiments, X203 reduced AKI-induced loss of kidney mass, limited renal fibrosis, and improved renal function while lowering inflammatory (Tnfα, Il6, Ccl2, Ccl5, Il1β), fibrosis (Col1a1, Col1a2, Col3a1, Fn1, Acta2) and tubular damage (Kim1, Ngal) markers (Fig. 3e; Supplementary Fig. 4a–f).